Clinical Use of Rivaroxaban

Pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications

Toby Trujillo, Paul P Dobesh

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Target-specific oral anticoagulants have become increasingly available as alternatives to traditional agents for the management of a number of thromboembolic disorders. To date, the direct Factor Xa inhibitor rivaroxaban is the most widely approved of the new agents. The dosing of rivaroxaban varies and adheres to specific schedules in each of the clinical settings in which it has been investigated. These regimens were devised based on the results of phase II dose-finding studies and/or pharmacokinetic modeling, and were demonstrated to be successful in randomized, phase III studies. In most cases, the pharmacodynamic profile of rivaroxaban permits once-daily dosing. A once-daily dose is indicated for the prevention of venous thromboembolism (VTE) in patients undergoing hip or knee replacement surgery, the long-term prevention of stroke in patients with non-valvular atrial fibrillation, and the long-term secondary prevention of recurrent VTE. Twice-daily dosing is required in the acute phase of treatment in patients with VTE and in the combination of rivaroxaban with standard single or dual antiplatelet therapy for secondary prevention after acute coronary syndrome events. This article reviews the empirical and clinical rationale supporting the dose regimens of rivaroxaban in each clinical setting.

Original languageEnglish (US)
Pages (from-to)1587-1603
Number of pages17
JournalDrugs
Volume74
Issue number14
DOIs
StatePublished - Sep 2 2014

Fingerprint

Pharmacokinetics
Venous Thromboembolism
Secondary Prevention
Acute Coronary Syndrome
Anticoagulants
Atrial Fibrillation
Hip
Knee
Appointments and Schedules
Stroke
Rivaroxaban
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Clinical Use of Rivaroxaban : Pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. / Trujillo, Toby; Dobesh, Paul P.

In: Drugs, Vol. 74, No. 14, 02.09.2014, p. 1587-1603.

Research output: Contribution to journalReview article

@article{c22fa560995a40a5aef1e310b69ec47e,
title = "Clinical Use of Rivaroxaban: Pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications",
abstract = "Target-specific oral anticoagulants have become increasingly available as alternatives to traditional agents for the management of a number of thromboembolic disorders. To date, the direct Factor Xa inhibitor rivaroxaban is the most widely approved of the new agents. The dosing of rivaroxaban varies and adheres to specific schedules in each of the clinical settings in which it has been investigated. These regimens were devised based on the results of phase II dose-finding studies and/or pharmacokinetic modeling, and were demonstrated to be successful in randomized, phase III studies. In most cases, the pharmacodynamic profile of rivaroxaban permits once-daily dosing. A once-daily dose is indicated for the prevention of venous thromboembolism (VTE) in patients undergoing hip or knee replacement surgery, the long-term prevention of stroke in patients with non-valvular atrial fibrillation, and the long-term secondary prevention of recurrent VTE. Twice-daily dosing is required in the acute phase of treatment in patients with VTE and in the combination of rivaroxaban with standard single or dual antiplatelet therapy for secondary prevention after acute coronary syndrome events. This article reviews the empirical and clinical rationale supporting the dose regimens of rivaroxaban in each clinical setting.",
author = "Toby Trujillo and Dobesh, {Paul P}",
year = "2014",
month = "9",
day = "2",
doi = "10.1007/s40265-014-0278-5",
language = "English (US)",
volume = "74",
pages = "1587--1603",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "14",

}

TY - JOUR

T1 - Clinical Use of Rivaroxaban

T2 - Pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications

AU - Trujillo, Toby

AU - Dobesh, Paul P

PY - 2014/9/2

Y1 - 2014/9/2

N2 - Target-specific oral anticoagulants have become increasingly available as alternatives to traditional agents for the management of a number of thromboembolic disorders. To date, the direct Factor Xa inhibitor rivaroxaban is the most widely approved of the new agents. The dosing of rivaroxaban varies and adheres to specific schedules in each of the clinical settings in which it has been investigated. These regimens were devised based on the results of phase II dose-finding studies and/or pharmacokinetic modeling, and were demonstrated to be successful in randomized, phase III studies. In most cases, the pharmacodynamic profile of rivaroxaban permits once-daily dosing. A once-daily dose is indicated for the prevention of venous thromboembolism (VTE) in patients undergoing hip or knee replacement surgery, the long-term prevention of stroke in patients with non-valvular atrial fibrillation, and the long-term secondary prevention of recurrent VTE. Twice-daily dosing is required in the acute phase of treatment in patients with VTE and in the combination of rivaroxaban with standard single or dual antiplatelet therapy for secondary prevention after acute coronary syndrome events. This article reviews the empirical and clinical rationale supporting the dose regimens of rivaroxaban in each clinical setting.

AB - Target-specific oral anticoagulants have become increasingly available as alternatives to traditional agents for the management of a number of thromboembolic disorders. To date, the direct Factor Xa inhibitor rivaroxaban is the most widely approved of the new agents. The dosing of rivaroxaban varies and adheres to specific schedules in each of the clinical settings in which it has been investigated. These regimens were devised based on the results of phase II dose-finding studies and/or pharmacokinetic modeling, and were demonstrated to be successful in randomized, phase III studies. In most cases, the pharmacodynamic profile of rivaroxaban permits once-daily dosing. A once-daily dose is indicated for the prevention of venous thromboembolism (VTE) in patients undergoing hip or knee replacement surgery, the long-term prevention of stroke in patients with non-valvular atrial fibrillation, and the long-term secondary prevention of recurrent VTE. Twice-daily dosing is required in the acute phase of treatment in patients with VTE and in the combination of rivaroxaban with standard single or dual antiplatelet therapy for secondary prevention after acute coronary syndrome events. This article reviews the empirical and clinical rationale supporting the dose regimens of rivaroxaban in each clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=84910628532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910628532&partnerID=8YFLogxK

U2 - 10.1007/s40265-014-0278-5

DO - 10.1007/s40265-014-0278-5

M3 - Review article

VL - 74

SP - 1587

EP - 1603

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 14

ER -